Department of Surgery, Myunggok Medical Research Center, Konyang University Hospital, Konyang University College of Medicine, 158, Gwanjeodong-ro, Seo-gu, Daejeon, 35365, South Korea.
Department of Internal Medicine, Myunggok Medical Research Center, Konyang University Hospital, Konyang University College of Medicine, Daejeon, Korea.
Surg Endosc. 2022 Jul;36(7):4748-4756. doi: 10.1007/s00464-021-08815-1. Epub 2021 Nov 3.
The optimal treatment for concomitant gallbladder (GB) stones with common bile duct (CBD) stones and predictors for recurrence of CBD stones are not established.
This single-center, retrospective study reviewed 466 patients diagnosed with a first event of concomitant GB stones with CBD stones from January 2010 to December 2018.
92 patients underwent single-stage laparoscopic CBD exploration (LCBDE) and laparoscopic cholecystectomy (LC) (group1), 108 underwent LCBDE + LC after endoscopic stone extraction (ESE) failure (group2), and 266 underwent ESE + LC (group3). Clearance (95.7 vs. 99.1 vs. 97.0%, p = 0.324) and recurrence rates (5.4 vs. 13.0 vs. 7.9%, p = 0.138) did not differ between groups. Group1 had fewer procedures (p < 0.001), lower post-treatment complication rates (7.6 vs. 18.5 vs. 13.9%, p = 0.082), and shorter hospital stay after the first procedure (5.7 vs 13.0 vs 9.8 days, p < 0.001). 40 patients (8.6%) had recurrence of CBD stones at mean follow-up of 17.1 months, of which 29 (72.5%) occurred within 24 months. In multivariate analysis, a CBD diameter > 8 mm, combined type-1 periampullary diverticulum, and age > 70 years were significant predictors of recurrence.
Single-stage LCBDE + LC is a safe and effective treatment for concomitant GB stones with CBD stones compared to ESE + LC. LCBDE should be considered in patients with a high risk of ESE failure. Careful follow-up is recommended for patients at high risk of recurrence of CBD stones, especially within 24 months after surgical or endoscopic treatment.
对于同时患有胆囊(GB)结石和胆总管(CBD)结石的患者,目前尚未确定最佳治疗方法和 CBD 结石复发的预测因素。
本单中心回顾性研究纳入了 2010 年 1 月至 2018 年 12 月期间首次诊断为同时患有胆囊结石和胆总管结石的 466 例患者。
92 例行一期腹腔镜胆总管探查术(LCBDE)+腹腔镜胆囊切除术(LC)(组 1),108 例行 LCBDE+内镜下碎石取石术(ESE)失败后 LC(组 2),266 例行 ESE+LC(组 3)。各组结石清除率(95.7%比 99.1%比 97.0%,p=0.324)和复发率(5.4%比 13.0%比 7.9%,p=0.138)差异无统计学意义。组 1 的手术次数更少(p<0.001),术后并发症发生率更低(7.6%比 18.5%比 13.9%,p=0.082),首次手术后的住院时间更短(5.7 天比 13.0 天比 9.8 天,p<0.001)。平均随访 17.1 个月后,40 例(8.6%)患者 CBD 结石复发,其中 29 例(72.5%)发生在 24 个月内。多因素分析显示,CBD 直径>8mm、Ⅰ型胆总管末端憩室合并、年龄>70 岁是复发的显著预测因素。
与 ESE+LC 相比,一期 LCBDE+LC 治疗同时患有胆囊结石和胆总管结石是一种安全有效的方法。对于 ESE 失败风险较高的患者,应考虑行 LCBDE。对于 CBD 结石复发风险较高的患者,应进行密切随访,特别是在手术或内镜治疗后 24 个月内。